{{위키데이터 속성 추적}}
{{Drugbox
|  image = Lobeglitazone.svg
 | Verifiedfields = 
  | verifiedrevid = 
 | IUPAC_name = 5-[(4-[2-([6-(4-Methoxyphenoxy)pyrimidin-4-yl]-methylamino)ethoxy]phenyl)methyl]-1,3-thiazolidine-2,4-dione
 | drug_name = Lobeglitazone

<!--Clinical data-->
 | tradename = 듀비에
 | routes_of_administration = 경구
 | legal_status = 전문의약품

| ATC_prefix = A10
| ATC_suffix = BG
| ATC_supplemental= 

<!--Pharmacokinetic data-->
| protein_bound = &gt;99%<ref name="pmid25648999">{{저널 인용| author = Lee JH, Noh CK, Yim CS, Jeong YS, Ahn SH, Lee W, Kim DD, Chung SJ. | title = Kinetics of the Absorption, Distribution, Metabolism, and Excretion of Lobeglitazone, a Novel Activator of Peroxisome Proliferator-Activated Receptor Gamma in Rats. | journal = Journal of Pharmaceutical sciences | volume = 104 | issue = 9 | pages = 3049-3059 | year = 2015 | pmid = 25648999 | doi = 10.1002/jps.24378 }}</ref>
| metabolism = 간 (CYP2C9, 2C19, and 1A2)<ref name="pmid25648999" />
| elimination_half-life = 7.8–9.8 hours<ref name="pmid22047812">{{저널 인용| author = Kim JW, Kim JR, Yi S, Shin KH, Shin HS, Yoon SH, Cho JY, Kim DH, Shin SG, Jang IJ, Yu KS. | title = Tolerability and pharmacokinetics of lobeglitazone (CKD-501), a peroxisome proliferator-activated receptor-γ agonist: a single- and multiple-dose, double-blind, randomized control study in healthy male Korean subjects. | journal = Clinical therapeutics | volume = 33 | issue = 11 | pages = 1819–1830 | year = 2011 | pmid = 22047812 | doi = 10.1016/j.clinthera.2011.09.023 }}</ref>


<!--Identifiers-->
| CAS_number = 607723-33-1
 | PubChem = 9826451
 | ChemSpiderID_Ref = 
 | ChemSpiderID = 8002194
|  synonyms = CKD-501

<!--Chemical data-->
 | C=24 | H=24 | N=4 | O=5 | S=1
 | molecular_weight = 480.53616 g/mol
 | smiles = CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC(=NC=N3)OC4=CC=C(C=C4)OC
 | InChI = 1S/C24H24N4O5S/c1-28(21-14-22(26-15-25-21)33-19-9-7-17(31-2)8-10-19)11-12-32-18-5-3-16(4-6-18)13-20-23(29)27-24(30)34-20/h3-10,14-15,20H,11-13H2,1-2H3,(H,27,29,30)
 | InChIKey = CHHXEZSCHQVSRE-UHFFFAOYSA-N
}}

'''로베글리타존'''(Lobeglitazone; 상품명 '''듀비에''', [[종근당]])은 [[티아졸리디네디온]] 계열의 [[당뇨병]]약이다. [[PPARα]]와 [[PPARγ]] 효능제로 작용해서 [[인슐린]] 민감성을 높인다.<ref name="pmid19577404">{{저널 인용| author = Lee JH, Woo YA, Hwang IC, Kim CY, Kim DD, Shim CK, Chung SJ. | title = Quantification of CKD-501, lobeglitazone, in rat plasma using a liquid-chromatography/tandem mass spectrometry method and its applications to pharmacokinetic studies. | journal = Journal of Pharmaceutical and Biomedical Analysis | volume = 50 | issue = 5 | pages = 872–877 | year = 2009 | pmid = 19577404 | doi = 10.1016/j.jpba.2009.06.003 }}</ref>

==효능 효과==
로베글리타존은 2013년 식품의약품안전처에서 허가 받았다. 2019년까지 시판 후 조사를 진행하는 조건으로 허가 받았다.<ref name="mfds_approval_press_release">{{뉴스 인용 | url = http://www.ckdpharm.com/customer/6_41_view.asp?seq=1532&code=66&dep1=6&dep2=4&dep3=1&Page.IsBack.list=JTJGY3VzdG9tZXIlMkY2JTVGNDElNUZsaXN0JTJFYXNwJTNGcGFnZSUzRDQlMjZkZXAxJTNENiUyNmRlcDIlM0Q0JTI2ZGVwMyUzRDE= | publisher = Chong Kun Dang press release | title = 국내개발 20번째 신약‘듀비에정’허가(20th new drug developed in Korea 'Duvie Tablet' was approved) | format =  | work =  | accessdate = 2014-10-23 | date = 2013-07-04 | 보존url = https://web.archive.org/web/20150923204439/http://www.ckdpharm.com/customer/6_41_view.asp?seq=1532&code=66&dep1=6&dep2=4&dep3=1&Page.IsBack.list=JTJGY3VzdG9tZXIlMkY2JTVGNDElNUZsaXN0JTJFYXNwJTNGcGFnZSUzRDQlMjZkZXAxJTNENiUyNmRlcDIlM0Q0JTI2ZGVwMyUzRDE= | 보존날짜 = 2015-09-23 | url-status = dead }}</ref><ref name="mfds_permission">{{웹 인용 | url = http://ezdrug.mfds.go.kr/kfda2?cmd=CCBAA02L2&itemSeq=201308005 | publisher = Ministry of Food and Drug Safety | work =  | title = MFDS permission information of Duvie Tablet 0.5mg | format = Release of Information | accessdate = 2014-10-23 | 보존url = https://web.archive.org/web/20160303213407/http://ezdrug.mfds.go.kr/kfda2?cmd=CCBAA02L2&itemSeq=201308005 | 보존날짜 = 2016-03-03 | url-status = dead }}</ref>

== 각주 ==
{{각주|2}}
{{전거 통제}}
[[분류:당뇨병약]]
[[분류:피리미딘]]